DRUG Stock Forecast: Bright Minds Biosciences, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Bright Minds Biosciences, Inc. is $110. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 17 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Bright Minds Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (76): The business earns solid, repeatable profits on what it owns.
Volatility (14): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
DRUG stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DRUG, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Nov 2026 | Baird | Maintains | Outperform | $126 → $107 |
| 2 Nov 2026 | BTIG | Maintains | Buy | $147 → $37 |
| 15 Oct 2026 | Wolfe Research | Initiates | Outperform | — |
| 19 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $145 |
| 17 Aug 2026 | BTIG | Reiterates | Buy | $147 |
| 1 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $145 |
| 20 May 2026 | Piper Sandler | Maintains | Overweight | — |
| 13 Apr 2026 | Jefferies | Initiates | Buy | — |
| 30 Mar 2026 | BTIG | Reiterates | Buy | — |
| 4 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Feb 2026 | BTIG | Maintains | Buy | — |
| 7 Jan 2026 | BTIG | Maintains | Buy | — |
| 6 Jan 2026 | BTIG | Maintains | Buy | — |
| 2 Jan 2026 | Chardan Capital | Maintains | Buy | — |
| 30 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Sept 2025 | BTIG | Initiates | Buy | — |
| 19 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 July 2025 | Cantor Fitzgerald | Assumes | Overweight | — |
| 21 May 2025 | Chardan Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for DRUG.
This page is one stock. Monday covers all of them.
DRUG appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
DRUG analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.9×
- EV / EBITDA
- —
Cheaper than 74% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −13.6%
- Return on assets
- −13.5%
- Dividend yield
- —
Higher than 35% of US stocks
Higher than 24% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bright Minds Biosciences, Inc. has a market value of $201.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$24.5M.
Free cash flow in the twelve months to 30 June 2026: −$24.7M.
Bright Minds Biosciences, Inc. employs 26 people.
Data provided by Twelve Data
DRUG and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at DRUG’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Bright Minds Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about DRUG
What is the DRUG stock price forecast for 2026-2027?
The median 12-month analyst price target for Bright Minds Biosciences, Inc. is $110, with estimates ranging from $36 to $146. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is DRUG stock a buy right now?
Of the 9 analysts covering Bright Minds Biosciences, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bright Minds Biosciences, Inc. 17 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank DRUG?
As at 21 Nov 2026, Bright Minds Biosciences, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (76 of 100).
Will DRUG stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts is $110, and Ticker Nerd's factor model ranks Bright Minds Biosciences, Inc. 17 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the DRUG stock forecast for 2030?
No analyst covering Bright Minds Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DRUG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $146 over the next 12 months.
What does Bright Minds Biosciences, Inc. do?
Bright Minds Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapeutics for neurological and psychiatric disorders. Bright Minds Biosciences Inc. works on next-generation compounds targeting serotonin receptor pathways, with programs aimed at conditions such as epilepsy, depression, pain, and other central nervous system disorders.
About Bright Minds Biosciences, Inc.
Bright Minds Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapeutics for neurological and psychiatric disorders. Bright Minds Biosciences Inc. works on next-generation compounds targeting serotonin receptor pathways, with programs aimed at conditions such as epilepsy, depression, pain, and other central nervous system disorders. The company’s research emphasizes selective small-molecule drug candidates designed to address severe and life-altering diseases with high unmet medical need. Its current business is centered on drug discovery and development, supported by a pipeline of preclinical and clinical programs in neurology and psychiatry. Bright Minds Biosciences Inc. operates as a research-driven biotech platform focused on advancing novel therapeutics from early development toward potential clinical use.
CEO Mr. Ian McDonald · 26 employees · United States · https://brightmindsbio.com